As a new way of reporting treatment effect, the restricted mean time in favor (RMT-IF) of treatment measures the net average time the treated have had a less serious outcome than the untreated over a
Single-arm studies are typically used in phase II of clinical trials, whose main objective is to determine whether a new treatment warrants further testing in a randomized phase III trial. The introdu
Unblinded interim analyses in clinical trials with adaptive designs are gaining increasing popularity. Here, the type I error rate is controlled by defining an appropriate conditional error function.
Interventions: TS-1+ Oxaliplatin+ Bevacizumab/TS-1+ Bevacizumab Primary outcome(s): DDC ; Duration of disease control Study Design: Single arm Non-randomized
